Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05730309
Other study ID # 2000034381
Secondary ID 000
Status Recruiting
Phase N/A
First received
Last updated
Start date October 15, 2023
Est. completion date August 2025

Study information

Verified date May 2024
Source Yale University
Contact Cristiana Baloescu, MD, MPH
Phone (203) 737-2644
Email cristiana.baloescu@yale.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of the proposed project is to quantify the prevalence and disparities of undiagnosed left ventricular hypertrophy (LVH) in Emergency Department (ED) patients with persistently elevated asymptomatic BP, and to measure the effect of disclosure, education, and expedited referral on 3-month outpatient follow-up and treatment rates for ED patients with newly diagnosed LVH by POCUS. Additionally, investigators will create a database of annotated clips for future development of a machine learning algorithm for LVH detection on POCUS.


Description:

The rationale for the proposed project is that, through bedside LVH detection, ED POCUS can be leveraged to identify those high-risk patients with asymptomatic hypertension (HTN) and improve disease prevention equity, while also ultimately decrease cardiovascular disease burden. The objective of the proposed project is to evaluate the feasibility and impact of LVH determination by POCUS on ED patients with elevated BP, and to quantify disparities in diagnosis and treatment. This study has 3 Aims: Aim 1: To quantify the prevalence and disparities of undiagnosed LVH in ED patients with persistently elevated asymptomatic BP. The investigators will enroll a prospective cohort of ED patients with BP > 140/90mmHg on two measurements who will receive POCUS to assess for LVH. The investigators hypothesize an overall LVH prevalence of at least 30%. Aim 2: To measure the effect of disclosure, education, and expedited referral on 3-month outpatient follow-up and treatment rates for ED patients with newly diagnosed LVH by POCUS. In a single arm feasibility clinical trial, subjects enrolled in the Aim 1 cohort with LVH on POCUS will receive the study intervention consisting of disclosure, counseling with set discharge instructions and expedited referral (communication to existing primary care physician OR referral to a follow-up clinic if no existing primary care). The investigators hypothesize a 50% follow-up rate and a 40% treatment rate. Aim 3: To create a database of annotated clips for development of an artificial intelligence (AI) algorithm for LVH detection on POCUS. A collection of annotated clips would support subsequent training, validation, and eventual integration into POCUS technology to facilitate larger scale screening and referral efforts. Aim 1 will have a prospective observational study design. Aim 2 will occur sequentially based on results of POCUS performed as part of Aim 1. Aim 3 will follow a repository creation protocol utilizing the ultrasound clips obtained during Aim 1. This study will lay the groundwork for future research to evaluate the impact of interventions informed by LVH assessment by POCUS on hypertension control, referral, and cardiovascular outcomes, as well as effectiveness of implementation strategies.


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date August 2025
Est. primary completion date August 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Two blood pressure measurements greater than 140 mmHg systolic and greater than 90 mmHg diastolic on two separate vital sign checks obtained as part of routine ED care Exclusion Criteria: - Subjects in extremis or lacking capacity to consent - Active treatment of hypertension within the last year - History of/known left ventricular hypertrophy - Active cardiac disease under the care of a cardiologist within last year - Suspicion for hypertensive emergency by treating ED physician - Admission to the hospital

Study Design


Intervention

Behavioral:
Customized discharge and expedited referral instructions
The intervention for subjects with LVH on research POCUS will consist of three elements: 1) disclosure of presence of LVH to subject, ED team and primary care physician (PCP) (if applicable); 2) educational discharge instructions describing high BP, HTN, LVH, implications for development of cardiovascular disease (such as development of heart failure, stroke), options for treatment (lifestyle, medications) and importance of follow-up; A preliminary version will be refined prior to the start of the trial by feedback from ED physicians and patients. Refinement will target content, phrasing, and literacy level. 3) referral to outpatient care, consisting of one of two options, based on whether the subject has an established PCP. For subjects with existing PCP, the study team will call the office, inform about study participation, LVH findings, and secure a follow-up appointment. For those with no PCP, study team will arrange for follow-up to special clinic.

Locations

Country Name City State
United States Yale New Haven Hospital New Haven Connecticut

Sponsors (1)

Lead Sponsor Collaborator
Yale University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Prevalence of LVH by POCUS LVH point prevalence will be determined based on ultrasound measurements of left ventricular wall thickness and/or left ventricular mass, expressed as percentage of total population enrolled in the study. Day 1
Secondary Prevalence of LVH stratified by race, ethnicity and gender Prevalence of LVH stratified by race, ethnicity and gender, if sample size allows this. LVH point prevalence by subgroups will be expressed as percentage of patients meeting LVH criteria of total enrolled population in that subgroup (eg men, women, African American, etc). through the end of the study, approximately 6 months
Secondary Rate of successful follow-up in group of subjects with LVH on POCUS Rate of successful follow-up in group of subjects with LVH on POCUS at 3 months post intervention, expressed as percentage of total subjects with successful follow-ups. Successful follow-up is defined as: a clinic appointment was made (either virtual or in-person) and subject presented to this appointment. 3 months post-intervention
Secondary Rate of treatment in group of subjects with LVH on POCUS Rate of treatment in group of subjects with LVH on POCUS at 3 months post intervention. Treatment is defined as new medication prescribed for blood pressure management following the ED visit where enrollment occurred. 3 months post-intervention
See also
  Status Clinical Trial Phase
Recruiting NCT03549559 - Imaging Histone Deacetylase in the Heart N/A
Completed NCT03332745 - Mechanism of Decompensation Evaluation - Aortic Stenosis
Completed NCT03322319 - Frequency of Cardiac Amyloidosis in the Caribbean's. (TEAM Amylose) N/A
Completed NCT01951404 - Does ALlopurinol Regress lefT Ventricular Hypertrophy in End Stage REnal Disease: The ALTERED Study Phase 4
Terminated NCT01188369 - Effects of Levosimendan in Patients Eligible for Aortic Valve Replacement With Left Ventricular Hypertrophy Phase 4
Completed NCT00344903 - Dallas Heart Study 2: Return Clinic Visit for the Dallas Heart Study Cohort N/A
Completed NCT00518479 - Pathophysiological Mechanisms of Hypertensive LVH:Optimising Regression N/A
Completed NCT00001632 - Investigation Into the Use of Ultrasound Technique in the Evaluation of Heart Disease N/A
Completed NCT00001534 - Long Term Effects of Enalapril and Losartan on Genetic Heart Disease N/A
Suspended NCT03193073 - Anemia Correction and Fibroblast Growth Factor 23 Levels in Chronic Kidney Disease , and Renal Transplant Patient N/A
Enrolling by invitation NCT05903313 - A Study to Evaluate Accuracy and Validity of the Chang Gung ECG Abnormality Detection Software
Recruiting NCT05646056 - A Noninterventional, Single-Center Feasibility Study to Evaluate Measures of Heart Failure Risk
Completed NCT01455974 - The Effects of Lowering Dialysate Sodium in Hypertensive Hemodialysis Patients N/A
Active, not recruiting NCT00418041 - Chronic Heart Failure Analysis and Registry in the Tohoku District 2 (CHART-2 Study) N/A
Completed NCT00602004 - Attenuation of Cardiac Effects of Arteriovenous Fistula Creation With Losartan N/A
Completed NCT00219141 - Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension Phase 3
Completed NCT03666351 - Study to Evaluate the Effect on Improvement of LVH by the Control of BP in Hypertension Patients With AV Disease Phase 4
Not yet recruiting NCT04022330 - Protective Monocytes and Macrophages to Limit Decompensation and Heart Damaging N/A
Recruiting NCT06169358 - Screening Patients With Fabry Disease in Patients With Hypertrophic Cardiomyopathy or Left Ventricular Hypertrophy
Recruiting NCT05179668 - SGLT2 Inhibition in Hemodialysis Phase 2